Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics develops next-generation therapies for severe autoimmune and inflammatory diseases as a clinical-stage biotechnology company. Its updates center on claseprubart, an investigational monoclonal antibody engineered to selectively inhibit the active form of C1s in the classical complement pathway, with programs in chronic inflammatory demyelinating polyneuropathy, generalized myasthenia gravis and multifocal motor neuropathy.
Recurring company news also covers FDA interactions and designations, clinical and preclinical program updates, financial results, public equity offerings, pre-funded warrants, and inducement equity grants under Nasdaq rules. Additional disclosures address DNTH212 and the company’s stated focus on rheumatology indications such as Sjögren’s disease, systemic lupus erythematosus and dermatomyositis.
Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards on July 1, 2026 to five newly hired, non-executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards are non-qualified stock options for an aggregate 58,000 shares at an exercise price of $90.21 per share, with a 10-year term and four-year vesting schedule.
Dianthus Therapeutics (Nasdaq: DNTH) started the global Phase 3 EMERGE trial of claseprubart in generalized myasthenia gravis (gMG) in AChR+ patients.
The placebo-controlled study will enroll ~195 participants, test Q2W and Q4W S.C. dosing, and target top-line results in 2H 2028.
Dianthus Therapeutics (Nasdaq: DNTH) granted equity inducement awards under Nasdaq Listing Rule 5635(c)(4) to three newly hired non-executive employees on June 1, 2026.
The awards are non-qualified stock options for an aggregate 60,000 shares at an exercise price of $89.45, with a 10-year term and a four-year vesting schedule.
Dianthus Therapeutics (Nasdaq: DNTH) will participate in two investor conferences in June 2026. Executives will join fireside chats and host one-on-one investor meetings at the Jefferies Global Healthcare Conference and the Goldman Sachs 47th Annual Global Healthcare Conference.
Live webcasts will be available via the company’s investor relations website under “News and Events”.
Dianthus Therapeutics (Nasdaq: DNTH) reported Q1 2026 results and program updates on May 5, 2026. Highlights include an early GO decision in the CAPTIVATE CIDP trial after 20 confirmed responders, FDA Orphan Drug Designation for claseprubart in Myasthenia Gravis, and a Phase 3 gMG trial on track to start in mid-2026 with top-line data expected in 2H'28.
Corporate: an upsized offering raised approximately $719 million, and cash totaled about $1.2 billion as of March 31, 2026, projected to provide runway into 2030. R&D and G&A rose; Q1 net loss was $40.8 million ($0.85 per share).
Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on May 1, 2026 to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). The grants total 135,000 non-qualified stock options with a 10-year term and an exercise price of $87.42 per share.
Options vest 25% after one year then monthly over 36 months and are governed by the company's Equity Inducement Plan and individual stock option agreements.
Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on April 1, 2026, to eight newly hired, non‑executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards are non‑qualified stock options for an aggregate of 135,000 shares, with a 10‑year term, $84.56 exercise price, and vesting of 25% after one year then monthly over 36 months; awards were approved by the independent Compensation Committee and are subject to the company equity inducement plan and option agreement.
Dianthus Therapeutics (Nasdaq: DNTH) closed an upsized underwritten public offering on March 12, 2026, raising approximately $719 million in aggregate gross proceeds before fees. The offering comprised 8,470,989 common shares (including 1,157,407 option shares) and pre-funded warrants to purchase 402,468 shares.
Pre-funded warrants were priced at $80.999 with a $0.001 exercise price and are exercisable immediately. Net proceeds will fund clinical and preclinical development, commercial readiness, working capital, and general corporate purposes.
Dianthus Therapeutics (Nasdaq: DNTH) priced an upsized underwritten public offering of 7,313,582 common shares at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999, with aggregate gross proceeds of approximately $625 million before fees.
The offering is expected to close on March 12, 2026, and underwriters have a 30-day option to purchase up to an additional 1,157,407 shares. Net proceeds will fund clinical/preclinical programs, commercial readiness, working capital, and general corporate purposes.
Dianthus Therapeutics (Nasdaq: DNTH) announced a proposed underwritten public offering of $400 million of common stock or, for some investors, pre-funded warrants, with a 30-day underwriter option for up to $60 million additional shares. The offering is subject to market and other conditions.
Dianthus intends to use net proceeds to advance clinical and preclinical development, commercial readiness activities, and for working capital and general corporate purposes. Joint book-running managers include Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair.